Diagnostic Microbiology & Infectious Disease
Volume 54, Issue 1 , Pages 51-56 , January 2006

Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa

  • Mark W. Garrison

      Affiliations

    • Corresponding Author InformationCollege of Pharmacy, Washington State University Spokane, PO Box 1495, Spokane, WA 99210-1495, USA. Tel.: +1-509-358-7658; fax: +1-509-358-7744.

Received 12 April 2005 ,Accepted 1 August 2005.

References 

  1. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 1997;40:639–651
  2. Bhavnani SM, Callen WA, Forrest A, Gilliland KK, Collins DA, Paladino JA, et al. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in US hospitals. Am. J. Health Syst. Pharm. 2003;60:1962–1970
  3. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine the importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 1987;31:1054–1060
  4. Burgess DS, Hall RG, Hardin TC. In vitro evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa. Diagn. Microbiol. Infect. Dis. 2003;46:131–137
  5. Chaplin-Robertson K, Edberg SC. Measurements of antibiotics in human body fluids: techniques and significance. In:  Lorian V editors. Antibiotics in laboratory medicine. 3rd ed.. Baltimore, MD: Williams and Wilkins; 1991;p. 313
  6. Chow AT, Fowler C, Williams RR, Morgan N, Kaminski S, Natarajan J. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 2001;45:2122–2125
  7. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimal inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J. Infect. Dis. 2004;189:1590–1597
  8. Dudley MN, Mandler HD, Gilbert D, Ericson J, Mayer KH, Zinner SH. Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin: studies in vivo and in an vitro dynamic model. Am. J. Med. 1987;82(Suppl 4A):363–368
  9. Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis. 2003;37:752–760
  10. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 1993;37:1073–1081
  11. Fridkin SK, Hill HA, Volkova NV, Edwards JR, Lawton RM, Gaynes RP, et al. Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg. Infect. Dis. 2002;8:697–701
  12. Friedland I, Gallagher G, King T, Woods GL. Antimicrobial susceptibility patterns in Pseudomonas aeruginosa: data from a multicenter intensive care unit surveillance study (ISS) in the United States. J. Chemother. 2004;16:437–441
  13. Garrison MW. Comparative activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J. Antimicrob. Chemother. 2003;52:503–506
  14. Garrison MW, Schimmels JA, Madaras-Kelly KJ. In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase IV. Diagn. Microbiol. Infect. Dis. 2003;47:587–593
  15. Gonzalez M, Moranchel A, Duran S. Multi-dose pharmacokinetics of ciprofloxacin administered intravenously to healthy volunteers. Antimicrob. Agents Chemother. 1985;28:235–239
  16. Jones RN, Mandell LA. Fluoroquinolones for the treatment of outpatient community-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 2002;44:69–76
  17. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Freidland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998–2001. Antimicrob. Agents Chemother. 2003;47:1681–1688
  18. Korvick JA, Yu VL. Antimicrobial agent therapy for Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1991;35:2167–2172
  19. Kuti JL, Nightingale CH, Nicolau DP. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob. Agents Chemother. 2004;48:2464–2470
  20. Lacy MK, Lu W, Xu X, Tessier PR, Nicolau DP, Quintiliani R, et al. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob. Agents Chemother. 1999;43:672–677
  21. Lister PD, Sanders CC. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J. Antimicrob. Chemother. 1999;43:79–86
  22. MacGowan AP, Wootton M, Holt HA. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility. J. Antimicrob. Chemother. 1999;43:345–349
  23. Madaras-Kelly KJ, Ostergaard BE, Hovde LB, Rotschafer JC. Twenty-four hour area under the concentration–time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 1996;40:627–632
  24. Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 2003;37:1405–1433
  25. National Committee for Clinical Laboratory Standards . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th ed.. Wayne, PA: NCCLS; 2003;(Approved standard NCCLS Document M7-A6, Vol 23, No 2)
  26. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA. 2003;289:885–888
  27. Rolston KVI, Frisbee-Hume S, LeBlanc B, Streeter H, Ho DH. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients. Diagn. Microbiol. Infect. Dis. 2003;47:441–449
  28. Tequin® (gatifloxacin tablets and injection) Gatifloxacin tablets/injection package insert. Bristol-Myers Squibb Company. Princeton, NJ 08543 (revised November 2004).
  29. West M, Boulanger BR, Fogarty C, Tennenberg A, Wiesinger B, Oross M, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized open-label study. Clin. Ther. 2003;25:485–506

PII: S0732-8893(05)00199-9

doi: 10.1016/j.diagmicrobio.2005.08.010

Diagnostic Microbiology & Infectious Disease
Volume 54, Issue 1 , Pages 51-56 , January 2006

Article Tools

* Image Usage & Resolution